PriceTargets.com logo

ViewRay - VRAY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.00
  • Forecasted Upside: ∞
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 07/26/2023 12:59 AM ET
+0 (0.00%)
Get New ViewRay Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRAY

Analyst Price Target is $1.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ViewRay in the last 3 months. The average price target is $1.00, with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for VRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in ViewRay. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2023Stifel NicolausLower Target$1.75 ➝ $1.00Low
5/11/2023B. RileyDowngradeBuy ➝ Neutral$4.00 ➝ $1.00Low
4/24/2023Piper SandlerLower Target$6.50 ➝ $2.00Low
4/17/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $1.25Low
4/14/2023Morgan StanleyLower TargetEqual Weight$5.50 ➝ $2.00Low
4/14/2023OppenheimerDowngradeOutperform ➝ Market Perform$8.00Low
4/14/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
4/14/2023Stifel NicolausDowngradeBuy ➝ Hold$7.00 ➝ $1.75Low
2/28/2023OppenheimerReiterated RatingOutperform$8.00Low
11/18/2022Morgan StanleyBoost TargetEqual Weight$5.00 ➝ $5.50Low
11/17/2022B. RileyReiterated RatingBuyLow
11/2/2022Morgan StanleyBoost TargetEqual Weight$4.50 ➝ $5.00Low
11/2/2022Piper SandlerBoost TargetOverweight$6.00 ➝ $6.50Low
10/20/2022BTIG ResearchLower Target$7.00Low
10/11/2022Morgan StanleyBoost TargetEqual Weight$4.00 ➝ $4.50Low
8/3/2022Piper SandlerLower TargetOverweight$7.00 ➝ $6.00Low
6/24/2022BTIG ResearchLower TargetBuy$9.00 ➝ $8.00Low
5/6/2022Piper SandlerLower Target$9.00 ➝ $7.00High
1/25/2022Stifel NicolausInitiated CoverageBuy$7.00High
1/11/2022B. RileyUpgradeNeutral ➝ Buy$7.00Medium
11/5/2021Piper SandlerBoost TargetOverweight$8.00 ➝ $9.00High
10/14/2021B. RileyInitiated CoverageNeutralHigh
6/25/2021Morgan StanleyUpgradeUnderweight ➝ Equal WeightHigh
5/7/2021GuggenheimUpgradeNeutral ➝ Buy$7.00High
3/26/2021BTIG ResearchUpgradeNeutral ➝ Buy$7.00High
1/12/2021Piper SandlerBoost TargetOverweight$4.00 ➝ $7.00Medium
1/6/2021Morgan StanleyBoost TargetUnderweight$2.00 ➝ $3.00N/A
11/6/2020Piper SandlerBoost TargetOverweight$3.50 ➝ $4.00High
10/28/2020B. RileyUpgradeNeutral ➝ Buy$2.75 ➝ $4.00High
6/23/2020OppenheimerReiterated RatingBuy$3.00Low
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$3.00Medium
6/8/2020Cantor FitzgeraldReiterated RatingOverweightHigh
6/3/2020BTIG ResearchReiterated RatingHoldHigh
5/1/2020OppenheimerReiterated RatingBuy$4.50 ➝ $3.00High
4/30/2020BTIG ResearchReiterated RatingHoldHigh
4/28/2020GuggenheimDowngradeBuy ➝ NeutralHigh
3/27/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$2.00High
3/13/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/13/2020B. RileyLower TargetNeutral$5.00 ➝ $2.50High
3/13/2020MizuhoReiterated RatingBuy$7.00Low
12/10/2019MizuhoReiterated RatingBuy$9.00Low
12/4/2019B. RileyReiterated RatingBuy ➝ Neutral$9.00 ➝ $5.00High
12/3/2019GuggenheimReiterated RatingBuy$8.00High
12/3/2019MizuhoReiterated RatingBuy$9.00High
11/13/2019Cantor FitzgeraldReiterated RatingOverweightHigh
10/22/2019OppenheimerInitiated CoverageOutperform$7.00High
10/15/2019Piper Sandler CompaniesSet TargetBuy$6.00Low
9/30/2019MizuhoSet TargetBuy$9.00Medium
9/13/2019Cantor FitzgeraldSet TargetBuy$6.00High
8/19/2019Northland SecuritiesReiterated RatingBuy$5.00Medium
8/12/2019Morgan StanleySet TargetHold$5.00Low
8/11/2019MizuhoReiterated RatingBuy$9.00High
8/9/2019Jefferies Financial GroupLower TargetBuy$14.00 ➝ $7.00Low
7/17/2019MizuhoReiterated RatingBuy$12.00Medium
6/18/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$15.00High
5/28/2019Cantor FitzgeraldSet TargetBuy$13.00Low
5/2/2019Cantor FitzgeraldReiterated RatingBuy$13.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ViewRay logo
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.34
Low: $0.03
High: $0.65

52 Week Range

Now: N/A

Volume

108,502,700 shs

Average Volume

7,510,055 shs

Market Capitalization

$4.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of ViewRay?

The following Wall Street sell-side analysts have issued research reports on ViewRay in the last year: B. Riley, Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for VRAY.

What is the current price target for ViewRay?

2 Wall Street analysts have set twelve-month price targets for ViewRay in the last year. Their average twelve-month price target is $1.00. Stifel Nicolaus has the highest price target set, predicting VRAY will reach $1.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $1.00 for ViewRay in the next year.
View the latest price targets for VRAY.

What is the current consensus analyst rating for ViewRay?

ViewRay currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VRAY, but not buy more shares or sell existing shares.
View the latest ratings for VRAY.

What other companies compete with ViewRay?

Other companies that are similar to ViewRay include Helius Medical Technologies, ENDRA Life Sciences, Nuwellis, Tivic Health Systems and BioSig Technologies. Learn More about companies similar to ViewRay.

How do I contact ViewRay's investor relations team?

ViewRay's physical mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company's listed phone number is (440) 703-3210 and its investor relations email address is [email protected]. The official website for ViewRay is www.viewray.com. Learn More about contacing ViewRay investor relations.